• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MICRO THERAPEUTICS, INC. DBA EV3 ONYX; AGENT, INJECTABLE, EMBOLIC

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MICRO THERAPEUTICS, INC. DBA EV3 ONYX; AGENT, INJECTABLE, EMBOLIC Back to Search Results
Model Number UNK-NV-ONYX
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Headache (1880); Intracranial Hemorrhage (1891); Dysphasia (2195); Unspecified Nervous System Problem (4426)
Event Date 11/08/2022
Event Type  Injury  
Manufacturer Narrative
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Medtronic received a report that the patient had progression of a subdural hematoma with new and worsening symptoms post procedure.The patient had headaches of increasing severity with associated intermittent word finding difficulties.The event was not associated with a seizure.There was a decline in mrs.The event resulted in hospitalization and was treated with a surgical procedure.The outcome status is recovering/resolving.The site assessed the event as not related to the device or procedure, however, the clinical events committee (cec) adjudicated the event as possibly related to the mma embolization procedure and causal to the disease under study.Additional information was received that the patient was undergoing treatment for a left chronic subdural hematoma with a 13.0mm thickness and a 0mm midline shift.The subject was able to complete and exit the study on (b)(6) 2023.
 
Manufacturer Narrative
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Event Description
Additional information was received that the event was recovered/resolved on (b)(6) 2023.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ONYX
Type of Device
AGENT, INJECTABLE, EMBOLIC
Manufacturer (Section D)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer (Section G)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer Contact
glen belmer
9775 toledo way
irvine, CA 92618
6122713209
MDR Report Key17710522
MDR Text Key322948461
Report Number2029214-2023-01619
Device Sequence Number1
Product Code MFE
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P030004
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Study,Health Professional
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 11/13/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberUNK-NV-ONYX
Device Catalogue NumberUNK-NV-ONYX
Device Lot NumberB383469
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 08/09/2023
Initial Date FDA Received09/08/2023
Supplement Dates Manufacturer Received10/16/2023
Supplement Dates FDA Received11/13/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Hospitalization;
Patient Age70 YR
Patient SexFemale
Patient Weight74 KG
-
-